JP2008519761A5 - - Google Patents

Download PDF

Info

Publication number
JP2008519761A5
JP2008519761A5 JP2007540066A JP2007540066A JP2008519761A5 JP 2008519761 A5 JP2008519761 A5 JP 2008519761A5 JP 2007540066 A JP2007540066 A JP 2007540066A JP 2007540066 A JP2007540066 A JP 2007540066A JP 2008519761 A5 JP2008519761 A5 JP 2008519761A5
Authority
JP
Japan
Prior art keywords
amino
carbonyl
trimethylphenyl
cyclohexyl
naphthalenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007540066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008519761A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/039956 external-priority patent/WO2006052722A1/en
Publication of JP2008519761A publication Critical patent/JP2008519761A/ja
Publication of JP2008519761A5 publication Critical patent/JP2008519761A5/ja
Pending legal-status Critical Current

Links

JP2007540066A 2004-11-09 2005-11-04 グリコーゲンホスホリラーゼ阻害化合物およびその医薬組成物 Pending JP2008519761A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62638904P 2004-11-09 2004-11-09
PCT/US2005/039956 WO2006052722A1 (en) 2004-11-09 2005-11-04 Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
JP2008519761A JP2008519761A (ja) 2008-06-12
JP2008519761A5 true JP2008519761A5 (cg-RX-API-DMAC7.html) 2008-10-16

Family

ID=35976487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540066A Pending JP2008519761A (ja) 2004-11-09 2005-11-04 グリコーゲンホスホリラーゼ阻害化合物およびその医薬組成物

Country Status (16)

Country Link
US (1) US20070249670A1 (cg-RX-API-DMAC7.html)
EP (1) EP1812383A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008519761A (cg-RX-API-DMAC7.html)
KR (1) KR20070086044A (cg-RX-API-DMAC7.html)
CN (1) CN101098852A (cg-RX-API-DMAC7.html)
AU (2) AU2005304962B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0517567A (cg-RX-API-DMAC7.html)
CA (1) CA2586446A1 (cg-RX-API-DMAC7.html)
IL (1) IL182863A0 (cg-RX-API-DMAC7.html)
MA (1) MA29090B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007005590A (cg-RX-API-DMAC7.html)
NO (1) NO20072223L (cg-RX-API-DMAC7.html)
RU (1) RU2007119427A (cg-RX-API-DMAC7.html)
SG (1) SG155229A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006052722A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200703713B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4765353B2 (ja) * 2004-03-22 2011-09-07 住友化学株式会社 (1−アルケニル)シクロプロパン化合物の製造方法
EP1676834A1 (en) 2004-12-30 2006-07-05 Sanofi-Aventis Deutschland GmbH Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5352454B2 (ja) 2006-06-28 2013-11-27 サノフイ Cxcr2アンンタゴニスト
EP2040690B1 (en) 2006-06-28 2014-08-06 Sanofi Inhibitors of cxcr2
CA2656150A1 (en) 2006-06-28 2008-01-03 Sanofi-Aventis New cxcr2 inhibitors
JP5352455B2 (ja) * 2006-06-30 2013-11-27 サノフイ Cxcr2阻害剤
GB0619611D0 (en) * 2006-10-04 2006-11-15 Ark Therapeutics Ltd Compounds and their use
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
EP2197845A1 (en) * 2007-09-28 2010-06-23 GlaxoSmithKline LLC Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
AU2008309003A1 (en) * 2007-09-28 2009-04-09 Glaxosmithkline Llc Glycogen phosphorylase inhibitor compound and pharmaceutical composition thereof
CN102083432B (zh) * 2008-05-05 2016-02-17 赛诺菲-安万特 酰基氨基取代的稠合环戊烷羧酸衍生物及它们作为药物的用途
JP2011525892A (ja) * 2008-06-18 2011-09-29 メルク・シャープ・エンド・ドーム・コーポレイション Janusキナーゼの阻害剤
WO2010092440A1 (en) * 2009-02-16 2010-08-19 Inserm (Institut National De La Sante Et De La Recherche Medicale) Cxcr2 receptor antagonists for the treatment or the prevention of insulin resistance
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
WO2011109470A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Heteroaryl nitrile compounds useful as inhibitors of cathepsin-s
WO2011159781A2 (en) * 2010-06-17 2011-12-22 Senomyx, Inc. Bitter taste modulators
ME02590B (me) 2012-06-26 2017-06-20 Bayer Pharma AG N- [4-(hinolin-4-iloksi)cikloheksil(metil)] (hetero)arilkarboksamidi kao antagonisti androgenog receptora, njihova proizvodnja i upotreba kao medicinski produkti
GB201211309D0 (en) * 2012-06-26 2012-08-08 Fujifilm Mfg Europe Bv Process for preparing membranes
CA2952897A1 (en) 2014-06-27 2015-12-30 Nogra Pharma Limited Aryl receptor modulators and methods of making and using the same
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
MX2019003425A (es) 2016-09-28 2019-08-16 Blade Therapeutics Inc Moduladores de calpainas y usos terapeuticos de los mismos.
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
TW202039473A (zh) 2018-12-19 2020-11-01 丹麥商理奧藥品公司 Il-17的小分子調節劑
EP3972963A1 (en) 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors
WO2021152113A1 (en) 2020-01-31 2021-08-05 Bayer Aktiengesellschaft Substituted 2,3-benzodiazepines derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59181257A (ja) * 1983-03-31 1984-10-15 Chugai Pharmaceut Co Ltd ウレイドベンズアミド誘導体
JPS61268678A (ja) * 1985-05-17 1986-11-28 バイエル・アクチエンゲゼルシヤフト 生産増進剤
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity
EA002124B1 (ru) * 1995-11-24 2001-12-24 Смитклайн Бичам С.П.А. Производные хинолина
JP4073489B2 (ja) * 1996-05-24 2008-04-09 ニューロサーチ・アクティーゼルスカブ 酸性基を有するフエニル誘導体、その製造方法及びそれをクロライドチャンネル遮断剤として使用する方法
DE69826695T2 (de) * 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1214292B1 (en) * 1999-09-24 2007-06-13 Genentech, Inc. Tyrosine derivatives
GB0008264D0 (en) * 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
PL374971A1 (en) * 2002-08-09 2005-11-14 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
AU2003258491A1 (en) * 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
AU2003280308A1 (en) * 2002-11-21 2004-06-15 Neurosearch A/S Aryl ureido derivatives and their medical use
US20070275962A1 (en) * 2003-09-10 2007-11-29 Gpc Biotech Ag Heterobicyclic Compounds as Pharmaceutically Active Agents
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
BRPI0508762A (pt) * 2004-04-16 2007-08-14 Genentech Inc método de aumento do esgotamento de células b em mamìferos, método de aumento da eficácia do esgotamento de células b, método de tratamento de malignidade ou neoplasma de células b, método de alìvio de disfunção autoimunológica regulada por células b, método de esgotamento das células b e composição

Similar Documents

Publication Publication Date Title
JP2008519761A5 (cg-RX-API-DMAC7.html)
RU2007119427A (ru) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
RU2215735C2 (ru) Производные аминомасляной, аминопентановой и аминогексановой кислот
RU2312860C2 (ru) Циклические ингибиторы протеинтирозинкиназ
RU2203897C2 (ru) Производные бензамидина, способ их получения, фармацевтическая композиция, способ ее получения и лекарственное средство
RU2001126559A (ru) Активаторы глюкокиназы
JP2005511746A5 (cg-RX-API-DMAC7.html)
JP2004502670A5 (cg-RX-API-DMAC7.html)
JP2014511869A5 (cg-RX-API-DMAC7.html)
JP2004534035A5 (cg-RX-API-DMAC7.html)
JP2013517283A5 (cg-RX-API-DMAC7.html)
AR048306A1 (es) Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40
JP2004509953A5 (cg-RX-API-DMAC7.html)
CA2436526A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
JP2014523897A5 (cg-RX-API-DMAC7.html)
RU2002128733A (ru) МОДУЛЯТОРЫ PPARγ
JP2009520686A5 (cg-RX-API-DMAC7.html)
JP2004523490A5 (cg-RX-API-DMAC7.html)
RU2009108275A (ru) Соединение сульфонамида или его соль
JP2011500679A5 (cg-RX-API-DMAC7.html)
RU2006124403A (ru) Новые производные тиазола
JP2013506637A5 (cg-RX-API-DMAC7.html)
RS65304A (sr) Supstituisani derivati metilen amida kao modulatori protein tirozin fosfataze (ptps)
AU2003239296A1 (en) Substituted methylene amide derivatives as Modulators of Protein Tyrosine Phosphatases (PTPs)
JP2008502614A5 (cg-RX-API-DMAC7.html)